Study looks at hospitalizations, prevalence of kidney disease among patients with COVID-19
Click Here to Manage Email Alerts
Chronic kidney disease and kidney failure were the most common comorbidities in patients hospitalized with COVID-19 in 46 states and the District of Columbia, according to research.
Those conditions accounted for 13% of all such patients from January 2020 to May 2020, according to FAIR Health, which has conducted four COVID-19 studies.
“[A]ll regions except one resembled the nation in having type 2 diabetes as the second most common comorbidity; the exception, the South, had hypertension in that rank,” according to a company press release that highlighted the study findings.
The data are based on an analysis of private health care claims, the company said.
FAIR Health also looked at other COVID-19 patient characteristics that included age, gender, rural vs. urban area by age, venue of care where first diagnosed, venue of care by age, comorbidities of hospitalized patients and median costs of hospitalization. The patient characteristics are analyzed nationally and also by U.S. census region, the company said.
Other findings from the study included the following:
Nationally, the median charge amount for hospitalization of a patient with COVID-19 ranged from $34,662 for the 23- to 30-year-old age group to $45,683 for the 51- to 60-year-old age group.
States in the West had the widest range of costs for COVID-19 hospitalizations, with median charge amounts ranging from $21,407 for the 19- to 22-year-old age group to $93,459 for the older than 70-years age group.
In the Northeast, telehealth was more common for initial diagnosis of COVID-19 than emergency rooms (6.7% vs. 6.2% of patients with COVID-19). The Northeast was the region with the highest percentage of patients with COVID-19 who received their initial diagnosis via telehealth.
Nationally, men were associated with a larger share (54%) of the distribution of COVID-19 claims than women (46%).
“Profiles of COVID-19 patients have many potential applications, including determining risk factors, influencing treatment protocols, setting priorities for eventual vaccination distribution, inspiring further research, and planning and budgeting for use of health care resources,” FAIR Health President Robin Gelburd said. “FAIR Health presents this report to help support that broad range of applications by stakeholders throughout the health care sector.”
FAIR Health is offering a webcast on July 16 from 2:00 p.m. to 3:00 p.m. EST detailing data from the company’s four COVID-19 studies. Info on registration is here.
Reference:
- https://www.healthcaredive.com/news/FAIR-health-kidney-disease-COVID-comorbidity/581576/
Collapse
Read more about
Click Here to Manage Email Alerts